Navigation Links
New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
Date:10/31/2011

ct, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon).   If not effectively treated, it may result in the need for surgery and hospitalization. Crohn's disease has been estimated to affect as many as half a million Americans.  People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives.

About Cimzia

Certolizumab pegol is the only PEGylated anti-TNF (Tumor Necrosis Factor).  It has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.  Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation.  This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases.  The U.S. Food and Drug Administration (FDA) has approved certolizumab pegol for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy.  It is also approved for the treatment of adults with moderately to severely active rheumatoid arthritis.  Certolizumab pegol was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn's disease who have not responded adequately to conventional treatment in September 2007.

Please visit www.cimzia.com for full prescribing information for CIMZIA®.

Important Safety Information

Risk of Serious Infections and Malignancy

Patients treated with CIMZIA are at an increased risk for developing serious infections that may lead to hospitalization or death.  Most patients who developed these infections we
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
2. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
3. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
4. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
5. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
6. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
7. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
10. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
11. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)...  Novartis Pharmaceuticals Corporation (NPC) has been named the top ... on the annual DiversityInc Top 50 Companies for Diversity listing. ... for Diversity on April 23 at an awards ceremony in ... second on the DiversityInc Top 10 Companies for Recruitment list ... Groups list. David Epstein , Division ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. (NYSE: ... and increased its five-year revolving credit facility to $120 ... accordion feature that will allow the company to increase ... $30.0 million, subject to securing additional commitments from existing ... the credit facility remains December 18, 2018.   ...
(Date:4/24/2015)... Spain , April 24, 2015  Elekta has ... Monaco® treatment planning system , enabling European clinics ... supports major treatment techniques including advanced 3D planning, IMRT, ... system. Monaco ... as well improved workflow efficiency. Advancements in 3D planning ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4Lannett Expands Revolving Credit Facility To $120 Million 2Elekta CE marks for Monaco v5.10 treatment planning system 2
... VALLEY FORGE, Pa., June 13, 2011 Saint-Gobain ... adding a variety of ergonomic features that improve ... and solution storage applications. These improvements are based ... laboratory and pharmaceutical environments. Manufactured from ...
... Today Divine Skin Inc. (DSKX), a developer of ... analgesic intended to compete over the counter with the ... to begin shipping upon final authorization by the Drug ... on underserved and niche categories, of course our pain ...
Cached Medicine Technology:New Bio-Simplex™ Polypropylene Carboys Feature Ergonomic Design, Versatile Closure Options 2New Bio-Simplex™ Polypropylene Carboys Feature Ergonomic Design, Versatile Closure Options 3Divine Skin Announces New Pain Reliever to Compete With Tylenol, Advil, Aspirin 2Divine Skin Announces New Pain Reliever to Compete With Tylenol, Advil, Aspirin 3
(Date:4/26/2015)... Italian public health researchers have released new data ... and other asbestos-related industries. Surviving Mesothelioma has just posted ... to read it now. , University researchers ... Medicine analyzed more than 15,000 cases of mesothelioma between ... asbestos cancer was most common. , “Asbestos cement ...
(Date:4/26/2015)... From March 18th, 2015 toward the ... Master™ Dahryn Trivedi, spent a month traveling in India ... institutions in the efforts of creating highly advanced, effective ... for human health care. , During their journey, ... institutions. All lab facilities are approved by the U.S. ...
(Date:4/26/2015)... In an article published last month in ... biomechanics occurring during the use of handheld electronic devices such ... that use of a tablet increases mechanical demand on neck ... more than when the neck is in a neutral position. ... pointing out the potential hazards of overuse of mobile technology ...
(Date:4/25/2015)... The National League for Nursing's ... endeavor to prepare nurses to provide high quality, culturally ... according to a new report by the John A. ... , The project began in 2007 as a ... direction of Elaine Tagliareni, EdD, RN, CNE, FAAN, professor ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair ... following statement following the deadly earthquake in Nepal: , ... in the deaths of more than 1,000 people. ... Nepal, Bangladesh, India and other parts of South Asia. ... the people of Nepal and the families of the ...
Breaking Medicine News(10 mins):Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3
... Feb. 7 PartnerRe Ltd.,(NYSE: PRE ) announced ... the period December 1, 2007 - February 29, 2008 ... Cumulative Redeemable Preferred Shares, and,$0.40625 per share on the ... will be payable on March 3, 2008, to,shareholders of ...
... NHS Choices ( http://www.nhs.uk ), the,online ,front door, ... information,resource, Health A-Z, aimed to help people find ... Based on NHS accredited information, the A-Z directory,( ... on a topic in seconds, providing them with ...
... that run on both conventional gasoline and stored ... gap until more sustainable technology is developed, according ... publication International Journal of Automotive Technology and Management, ... even slow development of more sustainable fuel-cell powered ...
... release was issued,today jointly by Schiffrin Barroway Topaz & ... DISTRICT COURT DISTRICT OF MARYLAND (NORTHERN DIVISION), ... LITIGATION Civil Action No. MJG 05-1224, SUMMARY ... ALL PERSONS AND ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED ...
... Comes With Software that Provides Hands-on Learning, ... a patient,s,medical records is essential to quality medical ... and death of a patient. Electronic Health,Record (EHR) ... make patient history readily available in those critical ...
... Environmental Health Groups Call for Immediate Moratorium on Bisphenol,A ... CHURCH, Va., Jan. 7 Dozens of state,and national ... for an immediate moratorium on the use of bisphenol ... containers, based on the results of a,new study that ...
Cached Medicine News:Health News:The trouble with hybrids 2Health News:Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation 2Health News:McGraw-Hill Higher Education Publishes Text on Innovative Electronic Health Records System 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 3Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 4
... Vitamin D kit is an enzymeimmunoassay for ... hydroxylated metabolites in serum or plasma. Calibrators, ... labelled 25-OH D. The diluted samples are ... with a highly specific sheep 25-OH D ...
... for the control of glucose metabolism. It ... of Langerhans as the precursor, proinsulin, which is ... are secreted in equimolar amounts into the portal ... of two polypeptide chains, the A-chain and B-chain ...
... is an integral part of the enzymatic ... II as well as the degradation of ... ACE is primarily located in endothelial cells. ... parameter for sarcoidosis and myocardial infarction but ...
... Retinol binding Proetin (RBP) is small (21kD) ... complex with pre-albumin in blood but loses ... been deliverd to the target cells. The ... the glomerulus and catabolized in the,renal tubules ...
Medicine Products: